Home › NDC Lookup › RxCUI directory › RxCUI 2374562

Dolutegravir 5 MG Tablet for Oral Suspension — RxCUI 2374562

RxNorm drug concept · Semantic clinical drug
RxCUI 2374562 Semantic clinical drug · SCD ● Current RxNorm concept 4 FDA products 4 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2374562
Official nameDolutegravir 5 MG Tablet for Oral Suspension
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdolutegravir 5 MG (as dolutegravir sodium) Tablet for Oral Suspension
FDA products mapped4
Package NDCs mapped4
Reported Medicaid activity (SDUD)95,552 prescriptions · 50 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dolutegravir: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • It treats HIV-1 infection and is always used with other HIV medicines. Tivicay can also be paired with rilpivirine as a complete regimen for certain adults whose HIV is already con...
  • No. You can take it with or without food. Just follow the schedule your prescriber gave you and keep it consistent.
  • The most common ones are trouble sleeping, tiredness and headache. Call your doctor about anything that bothers you or does not go away.
  • If you get a severe rash, a rash with fever, blisters or peeling skin, facial swelling, or trouble breathing, stop the medicine and get medical help. These can be signs of a seriou...
📖 Read our full Dolutegravir guide →

🕸️ Concept Web — How Dolutegravir 5 MG Tablet for Oral Suspension Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Dolutegravir 5 MG Tablet for Oral Suspension RxCUI 2374562

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Dolutegravir 1433868
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Tivicay 1433874
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dolutegravir Tablet for Oral Suspension 2374561
    • Dolutegravir Oral Liquid Product 2374560
    • Dolutegravir Oral Product 1433870
    • Dolutegravir Tablet for Oral Suspension [Tivicay] 2374564
    • Tivicay Oral Liquid Product 2374565
    • Tivicay Oral Product 1433877
    • Tablet for Oral Suspension 1861409
    • Oral Liquid Product 1151137
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 13 of 14 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dolutegravir 5 MG SCDC · 2374559
  • Dolutegravir Tablet for Oral Suspension SCDF · 2374561
  • Dolutegravir Oral Liquid Product SCDG · 2374560
  • Dolutegravir Oral Product SCDG · 1433870

Brand-Name Concepts

  • Dolutegravir 5 MG Tablet for Oral Suspension [Tivicay] SBD · 2374566
  • Dolutegravir 5 MG [Tivicay] SBDC · 2374563
  • Dolutegravir Tablet for Oral Suspension [Tivicay] SBDF · 2374564
  • Tivicay Oral Liquid Product SBDG · 2374565
  • Tivicay Oral Product SBDG · 1433877
  • Tivicay BN · 1433874

📦 FDA Products & Package NDCs

4 products · 4 package NDCs
4 package NDCs map to RxCUI 2374562 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
49702-0226-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-226-13) Tivicay ViiV Healthcare Company 2016-06-09
49702-0227-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-227-13) Tivicay ViiV Healthcare Company 2016-06-09
49702-0228-13 30 TABLET, FILM COATED in 1 BOTTLE (49702-228-13) Tivicay ViiV Healthcare Company 2013-08-13
49702-0255-37 1 BOTTLE in 1 CARTON (49702-255-37) / 60 TABLET, FOR SUSPEN... Tivicay PD ViiV Healthcare Company 2020-06-12
Observed labelers: ViiV Healthcare Company (4) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.